Multiple Myeloma and Related Disorders

Gösta Gahrton MD PhDProfessor, Department of Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm, SwedenBrian G.M. Durie MDAttending Physician, Department of Hematology and Oncology, Cedars-Sinai Comprehensive Cancer Centre, Los Angeles, CA, USADiana M. Samson MDSenior Lecturer in Haematology, Hammersmith Hospital, London, UK

• Part 1.History of multiple myeloma Epidemiology and etiology of plasma cell neoplasms Part 2.The immune system in myeloma Molecular biology and cytogenetics Biology of the malignant plasma cell Pathophysiology of myeloma bone disease Part 3.Clinical features Hematologic investigations: Morphologic and phenotypic Part 4.Biochemical and immunological investigations The role of imaging in multiple myeloma Innovative approaches for diagnosis and monitoring Differential diagnosis and prognosis Part 5.Principles of management Chemotherapy, steroids and interferon Radiotherapy Autologous stem cell transplantation Allogeneic transplantation and treatment with donor lymphocytes Supportive care Biological basis of therapy: New molecular targets Immunotherapeutic approaches Part 6.Management of bone disease Management of myeloma patients with renal failure Neurologic aspects of monoclonal gammopathy of undetermined significance, multiple myeloma, and related disorders Part 7.Monoclonal gammopathies of undetermined significance: the transition from MGUS to myeloma Solitary bone and extramedullary plasmacytoma Plasma cell leukaemia AL amyloidosis Heavy-chain diseases Waldenström’s disease

The publication of this book...has been well timed in that it offers a benchmark reference for the specialist in this field and provides the nonspecialist with a comprehensive overview of the discipline at the beginning of an exciting new period. A copy of this book should be available in every hematology department and on the shelf of every specialist in this field.New England Journal of MedicineAn impressive list of leaders in the myeloma field has been enrolled in the task to define the state-of-the-art in biology and clinical management of the disease, and the result is a book that is both scientifically sound and user-friendly.Annals of Oncology 16:337The authors are to be congratulated on this collection of detailed sections, whose logical sequence leads from basic research to the development of new molecular-targeted drugs.The Lancet Oncology